Join Growin Stock Community!

Codexis, inc.CDXS.US Overview

US StockHealthcare
(No presentation for CDXS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CDXS AI Insights

CDXS Overall Performance

CDXS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CDXS Recent Performance

1.49%

Codexis, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CDXS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CDXS Key Information

CDXS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CDXS Profile

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Price of CDXS

CDXS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CDXS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.72
PB Ratio
2.48
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
79.31%
Net Margin
-120.82%
Revenue Growth (YoY)
-17.87%
Profit Growth (YoY)
-14.23%
3-Year Revenue Growth
-37.04%
3-Year Profit Growth
-37.12%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.72
PB Ratio
2.48
Price-to-FCF
-
Gross Margin
79.31%
Net Margin
-120.82%
Revenue Growth (YoY)
-17.87%
Profit Growth (YoY)
-14.23%
3-Year Revenue Growth
-37.04%
3-Year Profit Growth
-37.12%
  • When is CDXS's latest earnings report released?

    The most recent financial report for Codexis, inc. (CDXS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CDXS's short-term business performance and financial health. For the latest updates on CDXS's earnings releases, visit this page regularly.

  • What is the operating profit of CDXS?

    According to the latest financial report, Codexis, inc. (CDXS) reported an Operating Profit of -18.95M with an Operating Margin of -220.31% this period, representing a decline of 14.45% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CDXS's revenue growth?

    In the latest financial report, Codexis, inc. (CDXS) announced revenue of 8.6M, with a Year-Over-Year growth rate of -32.98%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CDXS have?

    As of the end of the reporting period, Codexis, inc. (CDXS) had total debt of 68.62M, with a debt ratio of 0.55. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CDXS have?

    At the end of the period, Codexis, inc. (CDXS) held Total Cash and Cash Equivalents of 26.9M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CDXS go with three margins increasing?

    In the latest report, Codexis, inc. (CDXS) did not achieve the “three margins increasing” benchmark, with a gross margin of 71.3%%, operating margin of -220.31%%, and net margin of -228.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CDXS's profit trajectory and future growth potential.

  • Is CDXS's EPS continuing to grow?

    According to the past four quarterly reports, Codexis, inc. (CDXS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CDXS?

    Codexis, inc. (CDXS)'s Free Cash Flow (FCF) for the period is -7.88M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 43.37% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CDXS?

    The latest valuation data shows Codexis, inc. (CDXS) has a Price-To-Earnings (PE) ratio of -2.87 and a Price/Earnings-To-Growth (PEG) ratio of -0.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.